5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
Zacks Investment Research8/27/2026Neutral
AMRX
Amneal Pharmaceuticals, Inc. Class A Common StockNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$6.07B
P/E Ratio
36.33
EPS
$0.48
Beta
1.24
52W High
$19.26
52W Low
$9.49
50-Day MA
$17.76
200-Day MA
$14.37
Dividend Yield
—
Profit Margin
5.05%
Forward P/E
6.30
PEG Ratio
—
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Fundamentals
| Revenue (TTM) | $3.12B |
| Gross Profit (TTM) | $1.24B |
| EBITDA | $689.44M |
| Operating Margin | 18.30% |
| Return on Equity | 61.30% |
| Return on Assets | 8.60% |
| Revenue/Share (TTM) | $9.87 |
| Book Value | $0.10 |
| Price-to-Book | 188.52 |
| Price-to-Sales (TTM) | 1.95 |
| EV/Revenue | 2.852 |
| EV/EBITDA | 14.27 |
| Quarterly Earnings Growth (YoY) | 157.10% |
| Quarterly Revenue Growth (YoY) | 9.90% |
| Shares Outstanding | $348.30M |
| Float | $197.34M |
| % Insiders | 52.10% |
| % Institutions | 48.43% |
Historical Volatility
HV 10-Day
24.11%
HV 20-Day
34.17%
HV 30-Day
34.11%
HV 60-Day
33.95%
HV Rank
50.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($21.00 target)
2
Strong Buy2
BuyLatest News
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Zacks Investment Research8/20/2026Negative
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
Zacks Investment Research8/18/2026Positive
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
Zacks Investment Research8/12/2026Neutral
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
Zacks Investment Research8/12/2026Neutral
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
Zacks Investment Research8/12/2026Positive
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why
Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks Investment Research8/11/2026Positive
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research8/7/2026Positive
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.
Zacks Investment Research7/31/2026Positive
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Seeking Alpha7/30/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMRX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026